



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE

2nd Edition

CLSI EP35™

Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

CLSI EP35 provides recommendations for assessing clinically equivalent performance for additional similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types, such that the laboratory does not necessarily need to repeat the full measurement procedure validation for each specimen type. The recommendations in CLSI EP35 apply to both quantitative measurement procedures and qualitative examinations.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

Marvin Berman, PhD
Verena Hofmann, PhD
Jesper V. Johansen, PhD
Nils B. Person, PhD, FAACC
Kara SW Badjie, MS, MLS(ASCP)SBB, RT(CSMLS)
Abdel-Baset Halim, PharmD, PhD, DABCC

Kenneth Hoekstra, PhD, HCLD, FAACC
Marina V. Kondratovich, PhD
Qing H. Meng, PhD, MD, DABCC, FAACC
Victoria Petrides, MS
Richard Pfeltz, PhD

Abstract

Clinical and Laboratory Standards Institute EP35—*Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures* provides information for assessing clinically equivalent performance for additional similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types. During development, medical laboratory measurement procedures are typically validated for the most common specimen type. However, it can be clinically useful to test the measurand in multiple specimen types, including different fluids (eg, serum, plasma, whole blood, urine, cerebrospinal fluid, saliva), anticoagulants, and collection devices. By following the recommendations in CLSI EP35, developers of laboratory measurement procedures do not necessarily need to repeat the full measurement procedure validation for each specimen type. CLSI EP35 applies to both quantitative measurement procedures and qualitative examinations. CLSI EP35 is useful to developers of commercial and laboratory-developed tests and medical laboratory personnel.

Clinical and Laboratory Standards Institute (CLSI). *Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures*. 2nd ed. CLSI guideline EP35 (ISBN 978-1-68440-268-7 [Print]; ISBN 978-1-68440-269-4 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2025.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, and users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org



Copyright ©2025 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, or other product or material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

To read CLSI’s full Copyright Policy, please visit our website at <https://clsi.org/terms-of-use/>.

Suggested Citation

CLSI. *Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures*. 2nd ed. CLSI guideline EP35. Clinical and Laboratory Standards Institute; 2025.

Previous Edition:
December 2019

CLSI EP35-Ed2
ISBN 978-1-60440-268-7 (Print)
ISBN 978-1-68440-269-4 (Electronic)
ISBN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 44, Number 4

Committee Membership

Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

Document Development Committee on Equivalency of Specimen Types for Clinical Laboratory Methods

Nils B. Person, PhD, FAACC	Kenneth Hoekstra, PhD, HCLD, FAACC	Victoria Petrides, MS
Chairholder	PeaceHealth Laboratories	Abbott Laboratories
Siemens Healthineers	USA	USA
USA		
Karafa SW Badjie, MS, MLS(ASCP)SBB, RT(CSMLS) Mayo Clinic USA	Marina V. Kondratovich, PhD FDA Center for Devices and Radiological Health USA	Richard Pfeltz, PhD BD Life Sciences Diagnostic Systems USA
Abdel-Baset Halim, PharmD, PhD, DABCC Celldex Therapeutics USA	Qing H. Meng, PhD, MD, DABCC, FAACC The University of Texas M.D. Anderson Cancer Center USA	

Expert Panel on Evaluation Protocols

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

Acknowledgment

CLSI, the Consensus Council, the Expert Panel on Evaluation Protocols, and the Document Development Committee on Equivalency of Specimen Types for Clinical Laboratory Methods gratefully acknowledge the following volunteers for their important contributions to the limited revision of CLSI EP35:

Marvin Berman, PhD
Abbott Laboratories
USA

Verena Hofmann, PhD
Roche Diagnostics GmbH
Germany

Jesper V. Johansen, PhD
Radiometer Medical ApS
Denmark

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	1
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	4
Chapter 2: Protocol Overview	9
2.1 Equivalence Protocol Overview	10
2.2 Establishing Specimen Equivalence or Suitability Process Flow Charts	11
Chapter 3: Evaluation Plan Development	15
3.1 Risk Assessment	16
3.2 Evaluation Plan Content	16
3.3 Acceptance Criteria	16
Chapter 4: Experimental Protocols	19
4.1 Similar Specimen Type Experimental Protocol	20
4.2 Dissimilar Specimen Type Experimental Protocol	41
4.3 Specimen Transport and Stability	42
Chapter 5: Reporting of Claims in Product Labeling	45
Chapter 6: Conclusion	49
Chapter 7: Supplemental Information	51
References	52
Appendix A. Worked Example of a Quantitative Measurement Procedure, Plasma vs Serum	55
Appendix B. Worked Example of a Qualitative Examination, Plasma vs Serum	71
Appendix C. Calculating Confidence Intervals for Standard Deviation Ratios	76
The Quality Management System Approach	78

Foreword

For measurement procedures whose performance characteristics have previously been validated with a primary specimen type, CLSI EP35 provides recommendations for assessing clinically equivalent performance for other similar-matrix specimen types and suitable performance for dissimilar-matrix specimen types. These assessments provide verification options that do not repeat full measurement procedure validation for the additional specimen types, which include different fluids (eg, serum, plasma, whole blood, urine, cerebrospinal fluid, saliva), anticoagulants (eg, EDTA, citrate, oxalate), and collection devices (eg, gel barrier, plain tube). To date, there is no general guidance on requirements or protocols for demonstrating multiple specimen type equivalence or suitability for use on measurement procedures. Multiple sources provide guidance (eg, anticoagulant testing in CLSI EP07,¹ discussion of alternate body fluids in CLSI C49,² specimen collection tube evaluation in CLSI GP34³), but no CLSI documents provide the information as a cohesive whole. CLSI EP35 provides guidance on verifying clinically equivalent or suitable performance for additional specimen types without necessarily having to repeat the full measurement procedure validation for each specimen type. CLSI EP35 applies to both quantitative measurement procedures and qualitative examinations and is useful to developers of commercial and laboratory-developed tests and medical laboratory personnel.

Because measurement procedure performance characteristics can change when specimen types have substantially different matrix characteristics, evaluation of performance often needs to be based on suitability of the observed performance to the clinical requirements for the specific specimen type matrix rather than strict numerical equivalence. Therefore, access to the necessary clinical information is key to establishing equivalent or suitable performance for multiple specimen types, including the expected interval of measurand concentrations, inherent biological variability, medical decision levels, and any other relevant information for each specimen type. These characteristics can vary considerably between specimen types for the same measurand (eg, creatinine in serum vs urine). Once the necessary clinical information is available, the desirable measurement procedure performance attributes can be characterized for each specimen type based on risk assessment. After the performance requirements are established for each specimen type, the protocols described in CLSI EP35 can be used to document clinically equivalent or suitable performance.

Overview of Changes

CLSI EP35 was revised in 2024 under the Limited Revision Process and replaces the first edition of this guideline, which was published in 2019. Several changes were made in this edition, including:

- Reformatting to help improve readability
- Updating and aligning terminology
- Updating one dataset and figures to include the minimum number of 40 samples

NOTE: The content of CLSI EP35 is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

analytical specimen type

clinical equivalence

clinical suitability

equivalence

primary specimen type

specimen type

suitable

Currently in preview, click buy full version

.....

viii

Chapter ①

Introduction

Assessment of Equivalence or Suitability of Specimen Types for Medical Laboratory Measurement Procedures

1 Introduction

1.1 Scope

CLSI EP35 provides recommendations on establishing clinical equivalence or suitability for multiple specimen types for a single measurement procedure. This guideline provides a protocol for assessing equivalence or suitability for use of a different specimen type compared with the established primary specimen type for a medical laboratory measurement procedure or qualitative examination. CLSI EP35 provides a general framework for studies that establish equivalence among similar-matrix specimen types and clinical suitability among dissimilar-matrix specimen types. It also includes instructions for laboratory verification of alternate specimen types for commercial measurement procedures. This guideline applies to both quantitative measurement procedures and qualitative examinations. The intended users of CLSI EP35 are manufacturers, developers of medical laboratory measurement procedures, and laboratorians verifying alternate specimen types.

CLSI EP35 is intended to be used for specimen types for which the desired measurand has a known clinical indication and for which adequate clinical information is available to establish risk-based clinical performance goals. Establishing clinically based performance goals is beyond the scope of CLSI EP35.

CLSI EP35 focuses on the effect of specimen type on the analytical measurement procedure. There may also be preanalytical factors between specimen types that can affect results. These differences may require additional studies to characterize their effect on the results. Such preanalytical factors are outside of the scope of CLSI EP35.

1.2 Background

Medical laboratory measurement procedure performance characteristics are generally established and validated for use for the most commonly used specimen type for the measurand, which is designated as the primary specimen type. However, there is often a clinical need to measure the same measurand in a different specimen type (eg, urine rather than serum). Changing the specimen type can alter both the measurement procedure performance and the performance characteristics desirable for clinical use, so it is important to document that the measurement procedure performance characteristics are clinically acceptable with the candidate specimen type.

For specimen types with a similar matrix (eg, serum and plasma), the measurement procedure's performance can be tested for equivalence among specimen types. When the matrixes are dissimilar (eg, serum and urine), it might not be possible to establish equivalence (eg, because of different measuring intervals), but the new specimen type can still be shown to be clinically acceptable or suitable for use.

To assess specimen type equivalence or suitability, a definition of what constitutes equivalent or suitable performance is needed. Typically, equivalence is defined as the condition of being equal in value, worth, function, etc. In the context of establishing specimen types' equivalence or suitability for a measurement procedure, there are two primary scenarios.